Literature DB >> 30539869

Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.

J Long1, Tao Qu2, X F Pan1, X Tang1, H H Wan1, P Qiu1, Yan-Hua Xu1.   

Abstract

OBJECTIVE: To investigate the correlation between the expression of programmed death 1 (PD-1) and PD ligand-1 (PD-L1) in hepatocellular carcinoma (HCC) and clinical parameters.
MATERIALS AND METHODS: The study comprised tumor sections from 45 HCC patients treated with curative resection, which were evaluated for PD-1 and PD-L1 protein expression by immunohistochemistry.
RESULTS: PD-1 and PD-L1 expression was increased in cancers compared to adjacent normal tissues, with a positive rate of 37.78% (17/45) and 62.22% (28/45), respectively, which was positively correlated with the tumor stage and lymph node metastasis, negatively with postoperative prognosis. PD-1 positivity was most frequently observed in stromal tumor-infiltrating lymphocytes. The number of PD-1 positive lymphocyte was correlated with PD-L1 positive expression.
CONCLUSION: PD-L1 and PD-1 are overexpressed in HCC tissues. PD-L1 expression plays a critical role in the pathogenesis of human HCC, suggesting that it might be used as a new biomarker to predict the disease progression and prognosis.

Entities:  

Keywords:  Hepatocellular carcinoma; programmed death 1; programmed death ligand-1

Mesh:

Substances:

Year:  2018        PMID: 30539869     DOI: 10.4103/0973-1482.204850

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  3 in total

1.  The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Authors:  Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias
Journal:  Oncologist       Date:  2021-01-02

2.  Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.

Authors:  Qiu-Ju Sheng; Wen-Yue Tian; Xiao-Guang Dou; Chong Zhang; Yan-Wei Li; Chao Han; Yao-Xin Fan; Ping-Ping Lai; Yang Ding
Journal:  World J Gastrointest Oncol       Date:  2020-11-15

3.  Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Qian Zhang; Kexiang Zhou; Wei Liang; Wei Xiong
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.